FDA action counts
| Total FDA actions | 1 |
|---|---|
| Warning letters | 0 |
| Recalls | 0 |
| Approval records | 0 |
| Form 483 inspection citations | 1 |
| Most recent action | April 17, 2026 |
Risk pattern analysis
Argus HQ analysis — not an FDA finding
This section is Argus HQ analysis, not an FDA finding. Novel Laboratories, Inc. d.b.a Lupin Somerset has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Enforcement history
On 2026-04-17, Argus HQ recorded an FDA Form 483 inspection citation for Novel Laboratories, Inc. d.b.a Lupin Somerset, rated "high" severity in Argus HQ's classification: Novel Laboratories, Inc. d.b.a Lupin Somerset -- FDA 483: 1 observation (2026-04-17). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.
Frequently asked questions
- Does Argus HQ track new FDA actions for Novel Laboratories, Inc. d.b.a Lupin Somerset automatically?
- Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Novel Laboratories, Inc. d.b.a Lupin Somerset is observed, this page's event count and history update automatically.
- How many FDA actions does Argus HQ track for Novel Laboratories, Inc. d.b.a Lupin Somerset?
- 1 total: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.
- What is the most recent FDA action on file for Novel Laboratories, Inc. d.b.a Lupin Somerset?
- April 17, 2026. Argus HQ ingests new FDA enforcement records daily.
- Is this FDA enforcement data for Novel Laboratories, Inc. d.b.a Lupin Somerset official?
- Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
Every FDA action tied to this company, the week it happens.
Free weekly briefing. Real-time alerts on paid plans.
Related enforcement actions
Compare with
- Novel Laboratories, Inc. d.b.a Lupin Somerset vs Philips North America
- Novel Laboratories, Inc. d.b.a Lupin Somerset vs Medline Industries, LP
- Novel Laboratories, Inc. d.b.a Lupin Somerset vs Boston Scientific Corporation
- Novel Laboratories, Inc. d.b.a Lupin Somerset vs Baxter Healthcare Corporation
- Novel Laboratories, Inc. d.b.a Lupin Somerset vs PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.
Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Verified from FDA.gov · Last updated: Apr 17, 2026Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Actions Against Novel Laboratories, Inc. d.b.a Lupin Somerset. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/novel-laboratories-inc-d-b-a-lupin-somerset
"FDA Actions Against Novel Laboratories, Inc. d.b.a Lupin Somerset." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/novel-laboratories-inc-d-b-a-lupin-somerset.
Argus HQ Research. "FDA Actions Against Novel Laboratories, Inc. d.b.a Lupin Somerset." Digital Empire Holdings LLC. Accessed August 17, 2026. https://argushq.ai/company/novel-laboratories-inc-d-b-a-lupin-somerset.
@misc{argushq_argushq_ai_company_novel_laboratories_inc_d_b_a_lupin_somerset_2026,
title = {FDA Actions Against Novel Laboratories, Inc. d.b.a Lupin Somerset},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/company/novel-laboratories-inc-d-b-a-lupin-somerset},
note = {Accessed: August 17, 2026}
}Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗